Glaukos Reports Q2 Earnings, Revenue Tops Consensus
ByAinvest
Wednesday, Jul 30, 2025 9:16 pm ET1min read
GKOS--
Despite these positive results, the stock experienced a minor drop of 0.28% in aftermarket trading, closing at $93.5. With a market capitalization of $5.42 billion, InvestingPro analysis suggests the stock is currently trading above its Fair Value. The company's U.S. Glaucoma franchise led the growth, with sales surging by 45% year-over-year. International sales also showed strong performance, increasing by 20%.
CEO Thomas Burns attributed the record results to successful execution of strategic plans and advancing pipeline of novel technologies for chronic eye diseases. The company's full-year 2025 net sales guidance was raised to $480-$486 million, reflecting confidence in continued growth [1].
Key Takeaways:
- Glaukos Corp’s Q2 EPS outperformed expectations by 7.69%.
- Revenue grew 30% year-over-year, reaching $124.1 million.
- Stock price decreased by 0.28% in aftermarket trading.
- Full-year 2025 sales guidance was raised to $480-$486 million.
- Significant growth in U.S. Glaucoma franchise sales.
The company maintains impressive financial health metrics, including a strong current ratio of 6.49 and a moderate debt level, with total debt representing just 2% of total capital. According to InvestingPro data, the company has achieved a 10% revenue CAGR over the past five years [1].
References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-glaukos-corp-beats-q2-2025-earnings-estimates-stock-dips-93CH-4161505
Glaukos reported Q2 EPS of 24 cents, in line with consensus of 26 cents. Revenue reached $124.1M, surpassing the consensus of $115.5M. CEO Thomas Burns attributed the record results to successful execution of strategic plans and advancing pipeline of novel technologies for chronic eye diseases.
Glaukos Corp (GKOS) reported its Q2 2025 earnings on July 30, 2025, with an earnings per share (EPS) of -$0.24, slightly better than the forecast of -$0.26, marking a 7.69% surprise. Revenue reached $124.1 million, exceeding the expected $115.52 million by 7.35% [1].Despite these positive results, the stock experienced a minor drop of 0.28% in aftermarket trading, closing at $93.5. With a market capitalization of $5.42 billion, InvestingPro analysis suggests the stock is currently trading above its Fair Value. The company's U.S. Glaucoma franchise led the growth, with sales surging by 45% year-over-year. International sales also showed strong performance, increasing by 20%.
CEO Thomas Burns attributed the record results to successful execution of strategic plans and advancing pipeline of novel technologies for chronic eye diseases. The company's full-year 2025 net sales guidance was raised to $480-$486 million, reflecting confidence in continued growth [1].
Key Takeaways:
- Glaukos Corp’s Q2 EPS outperformed expectations by 7.69%.
- Revenue grew 30% year-over-year, reaching $124.1 million.
- Stock price decreased by 0.28% in aftermarket trading.
- Full-year 2025 sales guidance was raised to $480-$486 million.
- Significant growth in U.S. Glaucoma franchise sales.
The company maintains impressive financial health metrics, including a strong current ratio of 6.49 and a moderate debt level, with total debt representing just 2% of total capital. According to InvestingPro data, the company has achieved a 10% revenue CAGR over the past five years [1].
References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-glaukos-corp-beats-q2-2025-earnings-estimates-stock-dips-93CH-4161505
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet